Apellis Pharmaceuticals Inc (NASDAQ:APLS) Insider Trading Activity – CEO Sold 5,000 shares of Stock

ME Staff
-
0

Insider Trading Activity For Apellis Pharmaceuticals Inc (NASDAQ:APLS)

Cedric Francois , CEO of Apellis Pharmaceuticals Inc (NASDAQ:APLS) reportedly Sold 5,000 shares of the company’s stock at an average price of 27.82 for a total transaction amount of $139,100.00 SEC Form

Insider Trading History For Apellis Pharmaceuticals Inc (NASDAQ:APLS)

  • On 11/13/2017 Global Strategic Fund I Venbio, Major Shareholder, bought 127,515 with an average share price of $14.00 per share and the total transaction amounting to $1,785,210.00.
  • On 5/24/2018 Lukas Scheibler, Insider, bought 2,935 with an average share price of $20.37 per share and the total transaction amounting to $59,785.95.
  • On 9/14/2018 David O Watson, General Counsel, sold 15,776 with an average share price of $18.78 per share and the total transaction amounting to $296,273.28.
  • On 9/19/2018 Morningside Venture Investment, Major Shareholder, bought 140,000 with an average share price of $18.34 per share and the total transaction amounting to $2,567,600.00.
  • On 9/21/2018 Morningside Venture Investment, Major Shareholder, bought 81,323 with an average share price of $19.48 per share and the total transaction amounting to $1,584,172.04.
  • On 3/11/2019 Morningside Venture Investment, Major Shareholder, bought 441,176 with an average share price of $17.00 per share and the total transaction amounting to $7,499,992.00.
  • On 8/15/2019 Cedric Francois, CEO, sold 10,000 with an average share price of $26.80 per share and the total transaction amounting to $268,000.00.

    • Analyst Ratings History For Apellis Pharmaceuticals Inc (NASDAQ:APLS)

    • On 12/4/2017 Evercore ISI Initiated Coverage of rating Outperform
    • On 12/6/2018 Citigroup Boost Price Target of rating Buy with a price target of $34.00 to $40.00
    • On 1/8/2019 B. Riley Initiated Coverage of rating Buy with a price target of $40.00
    • On 3/28/2019 Robert W. Baird Initiated Coverage of rating Outperform to Outperform with a price target of $45.00
    • On 7/9/2019 Oppenheimer Initiated Coverage of rating Outperform with a price target of $52.00 to $52.00
    • On 7/12/2019 JPMorgan Chase & Co. Upgraded rating Neutral to Overweight with a price target of $35.00 to $49.00
    • On 7/31/2019 Cowen Set Price Target of rating Buy with a price target of $40.00

    Recent Trading Activity for Apellis Pharmaceuticals Inc (NASDAQ:APLS)
    Shares of Apellis Pharmaceuticals Inc closed the previous trading session at with shares trading hands.